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Purpose: The purpose of this analysis of patient-reported outcomes from the ELECT
(Evaluation of Lanreotide Depot/Autogel Efﬁcacy and Safety as a Carcinoid Syndrome
Treatment) trial (NCT00774930) was to explore the effect of lanreotide on symptoms of
carcinoid syndrome. Speciﬁcally, this post hoc analysis was designed to identify the most
important patient-reported outcomes for patients in ELECT.
Methods: The post hoc analysis of ELECT, a placebo-controlled study of lanreotide in
patients with neuroendocrine tumors, evaluated patient-reported outcomes during the double-
blind phase of the trial, speciﬁcally daily diarrhea and ﬂushing symptoms, octreotide rescue
use, and the EORTC QLQ-C30 and QLQ-GINET21 questionnaires at baseline and week 12.
Principal component (PC) analysis was applied on baseline data to identify independent
variable clusters and clinically meaningful summary measures that highly correlated to these
PCs. From those, the minimum clinical important differences were derived so to perform a
responder analysis.
Results: The three largest PCs captured 42.9% of the variation among baseline variables.
The C30 summary score (C30-SS), diarrhea burden, and ﬂushing burden were highly
correlated with PC1, PC2, and PC3, respectively. Lanreotide patients were more likely to
experience an improvement on the C30-SS (risk ratio [RR] 2.42; P=0.023), diarrhea burden
(RR 2.85; P=0.005), and ﬂushing burden (RR 1.39; P=0.31) compared to placebo patients.
Lanreotide-treated patients have a higher probability of being a responder on at least one of
the three domains of C30-SS, diarrhea burden, or ﬂushing burden compared to placebo
patients (RR 1.48; P=0.06).
Conclusion: The higher response rates in the diarrhea burden are consistent with the
previously reported effects of lanreotide on octreotide rescue medication use, while the
ﬁndings of a greater efﬁcacy of lanreotide vs placebo in the quality-of-life domains represent
a novel aspect in the beneﬁts of lanreotide.
Trial registration: ClinicalTrials.gov identiﬁer: NCT00774930.
Keywords: lanreotide, patient-reported outcomes, neuroendocrine tumors, NETs
Introduction
Neuroendocrine tumors (NETs) originate from pancreatic islet neuroendocrine
cells, diffuse gastroenteric neuroendocrine cells, and/or neuroendocrine cells else-
where in the body.1,2 The diffuse neuroendocrine system cells are scattered through-
out organs such as the esophagus, stomach, pancreas, small and large intestines, and
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lungs. Tumors arising from the diffuse neuroendocrine
system have been known for more than a century as
carcinoid, midgut, or gastrointestinal (GI) tumors.
NET is considered a rare form of cancer and is most
often of indolent nature, histopathologically well
differentiated,1 with a subset of patients who experience
symptomatic disease due to the production of bioactive
amines.3 Symptoms can be secondary to local tumor mass
effects or, most often, as a result of hepatic metastases and
evoked by the release of hormones (eg, serotonin) directly
into the systemic circulation.4 The ability to secrete bioac-
tive amines and the type of secretions varies widely across
neuroendocrine primary tumor types, with tumors arising
from the midgut (colon and small intestine) being most
likely to lead to carcinoid syndrome (CS).2 Serotonin-
induced CS often manifests as episodes of ﬂushing and
diarrhea5,6 and, in chronic cases, as right-sided valvular
heart disease.7
In many diseases, such as metastatic cancer, the goal of
therapy is to alleviate symptoms, increase daily function-
ing, and/or improve quality of life (QoL). Data reported
from patients are needed to understand the full impact of
disease in addition to clinical and laboratory assessments.8
Thus, to capture the impact of an intervention on subjec-
tive concepts such as symptom burden or functional
aspects, the US Food and Drug Administration (FDA)
recommends utilizing psychometrically validated patient-
reported outcome measures (PROMs) in clinical trials.9
Due to the symptomatic nature of NETs and the disease
impact on QoL, PROMs have become common in many
prospective, interventional clinical trials.10–13
Lanreotide has been recently shown to reduce the need
for subcutaneous (sc) octreotide for symptom control in
patients with CS through a Phase III, randomized, con-
trolled, double-blind trial (Evaluation of Lanreotide Depot/
Autogel Efﬁcacy and Safety as a Carcinoid Syndrome
Treatment [ELECT]).13 However, due to the heterogeneity
of the clinical manifestations of CS, it was anticipated that
no single measure would be able to broadly capture treat-
ment beneﬁt.
To comprehensively assess the effect of lanreotide
treatment on patients’ daily functioning, this post hoc
exploratory analysis deﬁned “carcinoid syndrome
response” using the set of patient-reported outcomes
from the ELECT study. Speciﬁcally, this post hoc analysis
further characterizes the effects of lanreotide on the con-
trol of symptoms associated with CS, with a focus on the
clinical meaningfulness of the patient-reported outcomes.
Principal component analysis (PCA) methodology was
used as an operator-independent method to select the
most relevant patient-reported outcomes. Although princi-
pal components are often challenging to understand clini-
cally, it may be helpful to replace the abstract principal
component by a highly correlated variable (“response
measure”) that is easier to understand from a clinical
point of view. To characterize potential CS response mea-
sures, correlations between each of three principal compo-
nents (PCs) and the PCA variables, as well as potentially
suitable composite score, were explored. For the primarily
QoL-driven PC1, the C30 summary score (C30-SS), which
was previously described and validated by Giesinger et al
(2016),14 was the most highly correlated variable
(r=0.943) and was therefore selected as a clinical proxy
for PC1 (Supplementary Annex 1, Table S1). This sum-
mary score combines all functional and symptom sub-
scales except for the QL (global quality of life) and FI
(ﬁnancial difﬁculties) subscales.
It was observed that for diarrhea and ﬂushing, respec-
tively, symptom frequency and severity contributed
equally to the loading of the respective PCs. Therefore,
diarrhea and ﬂushing composite “burden” variables were
calculated by averaging baseline symptom frequency and
severity. Burden of diarrhea (BD) showed the highest
correlation with PC2 (r=0.854), while burden of ﬂushing
(BF) showed the highest correlation with PC3 (r=0.725)
(Supplementary Annex 1, Table S1).
The clinical beneﬁt to the patient, referred to as “CS
response,” is characterized as the functional beneﬁt experi-
enced by the patient either in terms of an improvement in
symptom endpoints or in day-to-day functioning and QoL
endpoints. A further analysis conducted as part of this post
hoc investigation was the association between the primary
ELECT endpoint (ie, use of sc octreotide rescue medica-
tion) and a patient-reported CS response.
Methods
ELECT Phase III Clinical Trial
The ELECT study protocol and related materials were
reviewed and approved by an Independent Ethics
Committee/Institutional Review Board prior to com-
mencement of the study in all countries where the study
was conducted (refer to Supplementary Annex 2). The
study was conducted under the provisions of the
Declaration of Helsinki, and in accordance with the
International Conference on Harmonisation Consolidated
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Guideline on Good Clinical Practice. Informed consent
was obtained before initiation of any study-related proce-
dure and administration of the study treatment. ELECT
(ClinicalTrials.gov identiﬁer: NCT00774930) was a Phase
III, multicenter, double-blind (DB), placebo-controlled
randomized trial designed to evaluate the efﬁcacy of the
long-acting formulation of lanreotide 120 mg, compared
with placebo, administered every 4 weeks for the control
of symptoms associated with CS, through reduction in use
of short-acting sc octreotide.13 In brief, adult patients
(N=115) with a conﬁrmed NET and CS diagnosis who
were either treatment-naïve or whose CS symptoms were
responsive to conventional doses of octreotide LAR or sc
octreotide, were randomized and enrolled (1:1) to lanreo-
tide (n=59) or placebo (n=56) to participate in the trial.
The study consisted of a 28-day screening period (where
patient-based data on CS symptoms were collected) fol-
lowed by a 16-week double-blind phase in which patients
were able to cross over to an open-label extension phase
after 28 days if sc octreotide was taken for ≥21 days of the
28-day cycle and at a dose ≥300 μg/day for ≥14 of the 21
days, regardless of presence/absence of symptoms.
A multidimensional set of patient-reported outcomes
were evaluated, including CS symptoms, QoL, and rescue
medication endpoints, throughout the screening and DB
phases of the ELECT trial. Patients were required to report
the incidence and severity of the two most common and
bothersome CS symptoms (diarrhea and ﬂushing5,6) on a
daily basis using an interactive voice response system,
beginning at screening (4 weeks prior to baseline) and
through the DB phase of the study (baseline through 16
weeks). Patients reported if either diarrhea or ﬂushing was
present, the number of events on a daily basis, and the
overall event severity on a 3-point Likert scale (1 = mild, 2
= moderate, 3 = severe). The European Organisation for
Research and Treatment of Cancer core Quality of Life
Questionnaire module (EORTC QLQ-C30, version 3.0)
and 21-item disease-speciﬁc QoL for gastrointestinal
NETs (QLQ-GINET21) questionnaire were administered
at baseline and at week 12 of the DB phase. The QLQ-C30
is a multidimensional QoL questionnaire composed of six
multi-item functional scales (physical, role, cognitive,
emotional, social, three multi-item symptom scales [fati-
gue, nausea and vomiting, and pain]), six single-item
symptom scales (dyspnea, insomnia, appetite loss, consti-
pation, diarrhea, ﬁnancial impact), and a two-item global
quality-of-life scale (QL). The analysis focuses on the
QoL C30-SS only, rather than on the total 15 outcomes
separately, as recommended by the EORTC Quality of
Life Group. The QLQ-C30 summary score was found to
exhibit equal or superior known-groups validity and
responsiveness to change over time as compared to the
individual QLQ-C30 scales.14
Responder Analysis Through PCA
To assess CS response, the exploratory analysis consisted of
the following phases: (1) deﬁning the CS response measures
(through data reduction techniques); (2) deﬁning response
categories for each CS response measure by deriving mini-
mal clinically important differences (MCIDs); (3) assess-
ment of treatment efﬁcacy (responder analysis); and (4)
assessment of the association between the CS response
measures and the ELECT primary endpoint.
Principal component analysis was used to reduce the
dimensions of the available baseline patient-reported data.
Available data for analysis included the frequency and
severity of ﬂushing and diarrhea, as well as the EORTC
QLQ-C30 and QLQ-GINET21 subscale. The average per-
centage of days of sc octreotide use during screening was
included as a proxy for symptom severity. Correlation
coefﬁcients were generated to identify clinical proxies
for the identiﬁed PCs. In order to deﬁne patients as respon-
ders based on the identiﬁed PCs, the MCID was deﬁned
via a distribution-based method, the standard error of
measure, for the QoL score or through an anchor-based
method, the evaluation of receiver operator characteristic
(ROC) curves with the goal of maximizing true positives
and true negatives vs external anchor variables, for the
symptom-based scores. Additionally, the entire distribu-
tion of responders for treatment and control was explored
through cumulative distribution of response curves.9
Supplementary Annex 3 details recommended methods
and references for determining responsiveness and mini-
mal important differences for patient-reported outcomes
(PROs), as well as the approach followed in this analysis.
Having deﬁned the MCID for each CS response mea-
sure, patients were identiﬁed as responders for a given
measure if the improvement from baseline to week 12
exceeded the measure’s MCID. Patients were considered
non-responders if they showed symptom worsening, if
symptom improvement was smaller than the MCID, or if
they discontinued treatment or crossed over to the open-
label extension during the DB phase prior to week 12. A
composite CS response measure was generated, being
deﬁned as the number of patients with a clinically mean-
ingful improvement on at least one of the individual CS
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response measures. RRs comparing the lanreotide group
with placebo were calculated for all binary NET response
measures using exact methods and were tested by a chi-
square test at the 5% signiﬁcance level.
To assess the relationship between the ELECT primary
endpoint (percentage of days with rescue medication in the
DB period) and CS response, the association between the
percentage of days with rescue medication use in the CS
response measures was calculated using a logistical regres-
sion model with the binary NET response measures as
response variables and the percentage of days with rescue
medication in the DB period (the primary endpoint) as
continuous ﬁxed effect variable. The odds ratio (OR) was
utilized as a summary statistic and a chi-square test at the
5% signiﬁcance level was used to test for statistical signiﬁ-
cance. For further information, see Supplementary Annex 1.
Results
Responder Analysis Through PCA
The three ﬁrst PCs captured 24.5%, 10.3%, and 8.1%,
respectively, of the overall variation in the dataset, and
together accounted for 42.9% of the overall variation in
baseline patient-reported outcomes. PC1 was highly
(r=0.94) correlated with the EORTC QLQ C30-SS, with
an MCID of 5.65. PC2 and PC3 correlated best with mea-
sures that averaged the frequency and severity of diarrhea
and ﬂushing. These measures, classiﬁed as BD and BF, had
MCIDs of –0.62 and –0.31, respectively, with negative
changes from baseline exceeding the MCID, indicating
clinically meaningful improvement. Details on the compo-
sition of the PCs and the derivation of MCIDs are available
in Supplementary Annex 1 and Supplementary Annex 3,
respectively.
The results of the responder analysis are summarized in
Table 1. The lanreotide group had a higher response rate
for the C30-SS (RR=2.42; 95% CI=1.11–5.28) as well as
for BD (RR=2.85; 95% CI=1.31–6.17). For the BD end-
point, 36% (21/59) of lanreotide-assigned patients were
responders, compared to 13% (7/56) for the placebo-
assigned group (absolute risk difference = 23%; 95%
CI=8–38%). BF response rates were numerically higher
for lanreotide (RR=1.39; 95% CI=0.76–2.54). Among lan-
reotide-assigned patients, 58% (34/59) were composite
responders to at least one of C30-SS, BD, or BF, as
compared to 39% (21/54) of placebo patients (RR=1.48;
95% CI=0.99–2.21). Figure 1A–C are graphical represen-
tations of response to treatment through cumulative dis-
tribution function curves for C30-SS, BD, and BF,
respectively, from baseline to week 12. As demonstrated
by the curves, the response to lanreotide was generally
greater across the continuum regardless of the position of
the MCID.
The results of the logistic regression examining the
association between sc octreotide use during the DB
phase and the CS function response measures are summar-
ized in Table 2. For the BD and C30-SS responses, the
odds of a response decreased with increasing percentage of
days of rescue medication use in the 16-week DB period.
Discussion
The ELECT study reported a reduced need for sc octreo-
tide to control symptoms in patients with CS treated with
lanreotide compared to placebo. However, the importance
of this treatment effect in terms of patient-reported out-
comes has not been quantiﬁed yet. In this analysis, we
aimed to quantify the clinical beneﬁt of lanreotide on
patient-reported outcomes collected during the DB part
of the ELECT trial. We ﬁrst determined the most patient-
relevant outcomes, calculated a clinically meaningful dif-
ference for each, and compared the numbers of patients
who experienced a change from baseline larger than this
threshold.
Table 1 Overall Treatment Effect On The NET Function Responses, Classiﬁed As Responders Vs Non-Responders
Outcome Lanreotide (n=59) Placebo (n=56) RR 95% CI Pb
n/N % n/N %
C30 summary score 19/56 34 7/50 14 2.42 1.11–5.28 0.02
Diarrhea burden 21/59 36 7/56 13 2.85 1.31–6.17 0.005
Flushing burden 19/59 32 13/56 23 1.39 0.76–2.54 0.31
Composite scorea 34/59 58 21/55 39 1.48 0.99–2.21 0.06
Notes: aComposite score of diarrhea burden or ﬂushing burden or C30 summary score. bFisher’s exact test. P values are nominal and do not represent Type-I protected
hypothesis testing.
Abbreviations: CI, conﬁdence interval; n, number of responders; N, total patients in group; NET, neuroendocrine tumor; RR, risk ratio.
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Figure 1 Response to treatment for (A) theC30-SS frombaseline toweek 12, (B) the diarrhea burden frombaseline toweek 12, and (C) the ﬂushing burden frombaseline toweek 12.
Abbreviations: C30-SS, European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ) C30 summary score; MCID,
minimal clinically important difference.
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The current analysis highlights the important aspects of
QoL extending beyond CS symptoms (ie, diarrhea and
ﬂushing). The ﬁrst PC, which per deﬁnition captures the
largest amount of information from the patient-reported
dataset, was highly correlated to the C30-SS, indicating
that aspects of QoL related to patient daily functioning,
such as physical and emotional functioning, and nonspe-
ciﬁc symptoms like pain and fatigue are clearly important
to patients. These ﬁndings demonstrate that living with a
symptomatic, inoperable, and ultimately fatal tumor is
heavily affecting many facets of patients’ everyday lives.
Importantly, the PCA clearly identiﬁed the burdens of
diarrhea and ﬂushing as other relevant and distinct aspects
impacting patients’ lives. The analysis also showed an
association between increased sc octreotide use and
decreasing odds of responding on the C30-SS and BD,
conﬁrming the relevance of the primary endpoint in the
ELECT clinical trial, which showed that lanreotide signif-
icantly reduced the percentage of days of sc octreotide use
compared to placebo (absolute difference = –14.8%; 95%
CI = –26.8 to –2.8).13 This analysis contributes to translat-
ing the treatment effect on the primary outcome as
observed in the ELECT study into a functional outcome
that may be more meaningful from the perspective of the
patient.
The complex nature of evaluating QoL in NET patients
has been investigated in the previous observational
research, which has highlighted its importance in addition
to symptoms of CS.15–17 A recent patient survey using the
Patient-Reported Outcome Measure Information System
(PROMIS) and Short Form-36 (SF-36) questionnaires to
measure QoL in NET patients reported lower QoL com-
pared to the general population on all subscales, which
was primarily driven by patients with NET and CS.15 In
further analysis of the data, a signiﬁcant association was
found between the number of ﬂushing events and bowel
movements and QoL, with an increased prevalence and
severity of CS symptoms directly related to a reduction in
QoL.16 In an additional global survey of 1928 NET
patients, a large proportion of patients experienced diar-
rhea (48%) and ﬂushing (37%), with many reporting the
symptoms. Further, 92% of patients stated living with
NETs required lifestyle modiﬁcation daily (41% and
46%, respectively), including dietary and travel.17
The effects of somatostatin analogs on the symptoms
of CS have been well established.18 The ELECT trial
conﬁrmed the efﬁcacy of lanreotide in treating CS symp-
toms through the reduction of sc octreotide use compared
to placebo.13 Previous post hoc analyses of the ELECT
data have demonstrated that lanreotide patients were
responsive with respect to their reported reduction in the
symptoms of CS, and this was consistent across sub-
groups. In a post hoc analysis where patient-reported
symptom data were combined to provide an average
daily composite score, based on daily frequency and sever-
ity of symptoms, patients treated with lanreotide showed
greater reductions in diarrhea or ﬂushing compared with
patients treated with placebo.19 Further subgroup analysis
of ELECT found that the beneﬁt of lanreotide compared to
placebo, including greater CS symptom control, was con-
sistent across treatment-naïve and octreotide-experienced
patients, where lanreotide-treated subjects showed greater
carcinoid symptom control in both samples.20 Results
from the current analysis provide a deeper understanding
of the response to lanreotide across multiple domains.
This evaluation of the patient-reported outcomes pro-
vides additional insight into the direct clinical beneﬁts of
lanreotide in patients with CS. However, with 42.9% of the
baseline variation explained by the C30-SS, diarrhea bur-
den, and ﬂushing burden, the dataset is clearly multidimen-
sional, which, from a clinical perspective, is not surprising.
CS is characterized by an indolent course that may develop
over many years, and the expression of symptoms experi-
enced by individuals may be variable. Due to the hetero-
geneity of the clinical manifestations of CS, it was
anticipated that no single measure would be able to broadly
capture treatment beneﬁt. It is not unexpected, therefore,
that multifaceted QoL issues such as cognitive, physical,
role or social functioning, as well as fatigue, insomnia, body
image, appetite loss, and non-diarrhea GI symptoms, make
up such a large part of a patient’s experience
(Supplementary Annex 1, Figure S1A–C). Despite this,
Table 2 Association Of Percentage Of Days With Rescue
Medication In The 16-Week Double-Blind Period And NET
Function Responses
Outcome OR 95% CI Pb
C30 summary score 0.976 0.965–0.986 <0.001
Diarrhea burden 0.980 0.971–0.989 <0.001
Flushing burden 0.981 0.973–0.990 <0.001
Composite scorea 0.989 0.982–0.996 0.003
Notes: aComposite score of diarrhea burden and ﬂushing burden and C30 sum-
mary score. bLogistic regression using odds ratios. P values are nominal and do not
represent Type-I protected hypothesis testing.
Abbreviations: CI, conﬁdence interval; NET, neuroendocrine tumor; OR, odds
ratio.
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diarrhea and ﬂushing symptoms were clearly expressed as
the next most important PCs.
This analysis is not without limitations. First, it was
conducted as a post hoc evaluation and describes trends
that are descriptive in nature. The analysis was not statis-
tically powered, and no statistical conclusions can be
drawn from the data. To address this limitation, a PCA
methodology was chosen to characterize the interrelation-
ship of baseline patient-reported outcomes because it
allows for objective, data-driven choices in the selection
of relevant summary scores and composite variables.
Second, the ability to construct anchor-based MCIDs for
the patient-centered outcomes was limited. A consensus
regarding the appropriate method to determine MCID is
lacking. Additionally, in CS there is no established objec-
tive external criterion to distinguish responders from non-
responders on PRO patient-centered endpoints. Further,
the ELECT trial did not include a global assessment of
treatment efﬁcacy (by either the subject or the investiga-
tor). Efforts were made to translate PRO and MCID scores
into meaningful changes for the patients with CS, although
further research is needed to establish the most useful
concept of MCID such that it can alert the physician and
the patient that treatment is effective and impacts a
patient’s life or, alternatively, that a change in treatment
is required. Third, a proportion of patients could not qua-
lify as responders in this analysis. Of the total 115 patients
who were randomized, 39 (34%) and 44 (38%) of patients
had baseline BD and BF scores below the respective
MCID thresholds. By deﬁnition, such patients cannot
become responders in an MCID-deﬁned responder analy-
sis. It is possible that this lack of “responder potential”
within the study population played a role in the lack of
signiﬁcance for the ﬂushing burden endpoint. Composite
response scores were explored to mitigate this situation.
Additionally, the cumulative distribution function curves
provide important information that contextualizes the
results of the responder analysis. The curves clearly
demonstrate a difference in the percentage of responders
regardless of the chosen MCID in all three PCs when
comparing lanreotide- and placebo-treated patients.
Conclusions
We used PCA to identify the most important patient-
reported outcomes among the patients included in the
ELECT trial. The CS symptoms of diarrhea and ﬂushing
that have been previously reported as related to overall
QoL in patients with NETs were identiﬁed as the most
clinically relevant to patients. Treatment with lanreotide
resulted in improved response rates for the C30-SS and
BD scores after 12 weeks. Further, increased use of rescue
sc octreotide was associated with lower odds of response
to all three function response variables and overall com-
posite score, which suggests that increased use of short-
acting octreotide in the ELECT trial was associated with
poor QoL and CS symptom control. These ﬁndings high-
light that patient response to lanreotide treatment, not only
with respect to symptoms of CS, improves functional and
symptoms scores as indicated by the summary score of the
QoL instrument.
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